Q32 Bio Reports Bempikibart Data In Alopecia Areata

Q32 Bio

7.40 EUR -0.74%

• Charts
• News
• Analysen

Kaufen Verkaufen

(RTTNews) - Q32 Bio (QTTB) reported additional results from Part B of the Phase 2a SIGNAL-AA trial of bempikibart in patients with severe or very severe alopecia areata, presented at the EADV Congress 2026.

Bempikibart is an investigational fully human anti-IL-7Ra antibody designed to block IL-7 and TSLP signaling and re-regulate adaptive immune function.

In the 33-patient study, the mean reduction in SALT score from baseline was 35.3% at Week 36. In the modified intent-to-treat population, 40% of patients achieved a SALT-20 response, while 44% achieved SALT30 and SALT50 responses.

Responses were also maintained or deepened during the 16-week off-drug period. Among 18 patients followed off treatment, 44% achieved SALT-20, 61% achieved SALT30 and 50% achieved SALT50 responses at Week 52.

Q32 Bio said bempikibart was generally well tolerated, with no new safety signals or treatment-related serious adverse events. The company plans to advance bempikibart into a registration-directed program for severe or very severe alopecia areata in the first half of 2027.

Currently, QTTB is trading at $9.57, up 0.21%.